{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-026739","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.154405+00:00","generated_at":"2026-06-14T05:39:24.307181+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enanta EDP-235 shows 0.8-1.0 log viral load decline in Phase 2 COVID-19 trial subset","bullets":["In nucleocapsid-negative patients, 400mg EDP-235 showed 0.8 log viral load decline vs placebo at Day 5.","In subset treated within 3 days of symptom onset, 1.0 log viral load decline seen at Day 5.","Results support further development of EDP-235 for COVID-19.","Updated corporate presentation with additional SPRINT analyses posted on website June 7, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-026739","json":"https://secwatch.observer/filing/0000950170-23-026739.json","markdown":"https://secwatch.observer/filing/0000950170-23-026739.md","text":"https://secwatch.observer/filing/0000950170-23-026739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023026739/0000950170-23-026739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023026739/enta-20230607.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:39:24.307181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}